SecSonar.com

Cellectis S.A. (CLLS)

Cellectis S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Cellectis S.A. (CLLS) is a Biotechnology company based in FR with a market capitalization of $354.5M. Revenue grew 75.8% year-over-year and free cash flow was negative at -$42.5M. This page tracks CLLS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

FR · 216 employees · IPO Mar 24, 2015

Valuation

Valuation & price

$3.70 · as of May 26, 2026 · -30.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.67

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$5.24$3.42$1.59Jul 25Dec 25Jul 26Jul 7, 25$1.60Jul 9, 25$1.63Jul 11, 25$1.59Jul 15, 25$2.11Jul 17, 25$1.93Jul 21, 25$1.83Jul 23, 25$2.33Jul 25, 25$2.52Jul 29, 25$2.81Jul 31, 25$2.51Aug 4, 25$3.02Aug 6, 25$2.71Aug 11, 25$2.65Aug 13, 25$2.79Aug 15, 25$2.85Aug 19, 25$2.98Aug 21, 25$2.77Aug 25, 25$2.69Aug 27, 25$2.67Aug 29, 25$2.57Sep 3, 25$2.59Sep 5, 25$2.68Sep 9, 25$2.85Sep 11, 25$2.98Sep 16, 25$3.16Sep 18, 25$3.16Sep 22, 25$3.67Sep 24, 25$3.47Sep 26, 25$3.36Sep 30, 25$2.85Oct 2, 25$3.42Oct 6, 25$3.53Oct 8, 25$4.30Oct 10, 25$4.04Oct 14, 25$4.17Oct 16, 25$4.52Oct 21, 25$3.68Oct 23, 25$3.47Oct 27, 25$3.63Oct 29, 25$3.63Oct 31, 25$3.45Nov 4, 25$3.28Nov 6, 25$3.13Nov 10, 25$3.55Nov 12, 25$3.65Nov 14, 25$3.90Nov 18, 25$4.11Nov 20, 25$4.78Nov 25, 25$5.24Nov 28, 25$5.07Dec 2, 25$4.71Dec 4, 25$4.83Dec 8, 25$4.62Dec 10, 25$5.13Dec 12, 25$4.68Dec 16, 25$4.06Dec 18, 25$4.16Dec 22, 25$4.69Dec 24, 25$4.84Dec 29, 25$4.96Jan 2, 26$4.80Jan 6, 26$4.40Jan 8, 26$4.48Jan 12, 26$4.26Jan 14, 26$4.27Jan 16, 26$4.07Jan 21, 26$4.11Jan 23, 26$4.42Jan 27, 26$4.23Jan 29, 26$3.99Feb 2, 26$3.82Feb 4, 26$3.54Feb 9, 26$3.72Feb 11, 26$3.65Feb 13, 26$3.73Feb 18, 26$4.06Feb 20, 26$3.90Feb 24, 26$3.98Feb 26, 26$4.02Mar 2, 26$3.80Mar 4, 26$3.75Mar 6, 26$3.56Mar 10, 26$3.82Mar 12, 26$3.33Mar 17, 26$3.45Mar 19, 26$3.48Mar 23, 26$3.42Mar 25, 26$3.37Mar 27, 26$3.08Mar 31, 26$3.17Apr 2, 26$3.41Apr 7, 26$3.36Apr 9, 26$3.50Apr 13, 26$4.28Apr 15, 26$4.09Apr 17, 26$4.42Apr 22, 26$3.98Apr 24, 26$3.89Apr 28, 26$4.00Apr 30, 26$3.90May 4, 26$3.70May 6, 26$3.95May 8, 26$3.85May 12, 26$3.96May 14, 26$4.07May 18, 26$3.85May 20, 26$3.66May 22, 26$3.50May 28, 26$3.63Jun 1, 26$3.48Jun 3, 26$3.09Jun 5, 26$3.06Jun 9, 26$2.99Jun 11, 26$3.09Jun 15, 26$3.11Jun 17, 26$3.08Jun 22, 26$2.82Jun 24, 26$2.79Jun 26, 26$2.83Jul 2, 26$3.30
$1.5952-week range$5.35
Loading valuation history…

Fundamentals

Key fundamentals

$354.5M

Market cap

75.8%

Revenue growth (YoY)

86.6%

Gross margin

-$42.5M

Free cash flow (USD)

-$88.8M

Net debt

Net cash position

10.7%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$42.6MFY 2017$25.2MFY 2018$12.7MFY 2019$15.2MFY 2020$51.1MFY 2021$30.3MFY 2022$19.2MFY 2023$755.0KFY 2024$41.5MFY 2025$72.9M
$42.6M$72.9M

Free cash flow by year

2016 → 2025

FY 2016$-44.4MFY 2017$-55.0MFY 2018$-73.0MFY 2019$-82.1MFY 2020$-124.7MFY 2021$-123.1MFY 2022$-89.9MFY 2023$-25.8MFY 2024$19.5MFY 2025$-42.5M
-$44.4M-$42.5M

Gross margin by year

2021 → 2025

FY 202193.9%FY 202255.8%FY 2023-882.6%FY 202477.9%FY 202586.6%
93.9%86.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K/A filed Jun 26, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Annual reportAnnual Report FiledJun 26, 2026Filing
  • 6-K filingShareholders Meeting ResultsJun 25, 2026Filing
  • Annual reportAnnual Report FiledJun 25, 2026Filing
  • 6-K filingClinical Trial Results PresentationJun 11, 2026Filing
  • 6-K filingFDA RMAT DesignationJun 9, 2026Filing
  • Annual reportAnnual Report FiledMay 21, 2026Filing
  • 6-K filingAnnual Shareholders MeetingMay 20, 2026Filing
  • 6-K filingClinical Data PresentationMay 12, 2026Filing
  • Annual reportAnnual Report FiledMay 11, 2026Filing
  • Quarterly reportQuarterly Report FiledMay 11, 2026Filing

Questions

Frequently asked questions

What is Cellectis S.A.'s market cap?

Cellectis S.A. (CLLS) has a market capitalization of $354.5M.

What is CLLS's P/E ratio?

A meaningful P/E ratio is not available for CLLS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CLLS's price-to-book (P/B) ratio?

CLLS trades at 4.67 times book value per share.

Are insiders buying CLLS stock?

SEC Form 4 filings show no open-market insider buys at Cellectis S.A. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

OVID

Ovid Therapeutics Inc.

$360M

KROS

Keros Therapeutics, Inc.

$361.9M

IRD

Opus Genetics, Inc.

$364.7M

PBYI

Puma Biotechnology, Inc.

$364.7M

RGNX

REGENXBIO Inc.

$365.2M

PALI

Palisade Bio, Inc.

$366.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.